CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial

Launched by RENJI HOSPITAL · Apr 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new method to detect circulating tumor cells (CTCs) in women with breast cancer who have already undergone treatment and surgery. The goal is to see if these CTCs can provide important information about a patient's prognosis, which means how likely they are to recover or face challenges after their treatment. The study uses a device called the GILUPI CellCollector®, which is designed to collect these cells from the blood.

To participate in this trial, women aged 18 to 70 who have been diagnosed with invasive breast cancer and have completed both neoadjuvant treatment (which is treatment given before surgery) and surgery within the last four years can apply. However, women with advanced cancer that has spread, those who are pregnant or breastfeeding, or those with certain infections cannot participate. If eligible, participants will have their blood tested for these circulating tumor cells, and they will be contributing to important research that could help improve future breast cancer treatment and care.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female, aged ≥18 and ≤70 years;
• • Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);
• • Completed neoadjuvant treamtment and surgery (within 4 years after surgery);
• • Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);
• • ECOG 0-1
• Exclusion Criteria:
• • Metastatic disease (Stage IV);
• • Female patients who are pregnancy or lactation;
• • Uncontrollable puncture site infection or systemic infection;